Results 21 to 30 of about 16,628 (221)

A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. A high platelet count, or thrombocytosis, is either a reactive process or a result of a myeloproliferative disorder. Ankylosing spondylitis is a chronic inflammatory rheumatic disease affecting the spine and sometimes peripheral ...
Zeremski Vanja, Savić Aleksandar, Ilić Tatjana, Milošević Ivana, Maksimović Marina, Vučković Biljana   +5 more
doaj   +1 more source

Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022

Научно-практическая ревматология, 2023
The article presents updated guidelines developed by the American College of Rheumatology and the American Association of Hip and Knee Surgeons on the perioperative treatment of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic ...
V. N. Amirjanova, M. A. Makarov, A. E. Karateev, A. E. Khramov, S. V. Maglevaniy, A. V. Rozov, V. A. Nesterenko, E. L. Nasonov   +7 more
doaj   +1 more source

CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS: LATEST DATA

Научно-практическая ревматология, 2016
The paper gives the latest data on the impact of traditional cardiovascular risk factors, chronic inflammation, antirheumatic therapy (disease-modifying antirheumatic drugs and biological agents) on the cardiovascular system.
T. V. Popkova, D. S. Novikova, E. L. Nasonov   +2 more
doaj   +1 more source

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis

Arthritis Research & Therapy, 2017
Background Biologic disease-modifying antirheumatic drugs (DMARDs) are increasingly used for rheumatoid arthritis (RA) treatment. However, little is known based on contemporary data about the factors associated with DMARDs and patterns of use of biologic
Yinzhu Jin, Rishi J. Desai, Jun Liu, Nam-Kyong Choi, Seoyoung C. Kim   +4 more
doaj   +1 more source

Frequency and Effective Factors on Discontinuation of Treatment in Patients with Inflammatory Rheumatic Diseases

Journal of Mazandaran University of Medical Sciences, 2022
Background and purpose: Treatment of rheumatic diseases depends on proper use of medications. The aim of this study was to evaluate the frequency and reasons for discontinuation of drugs in these patients.
Maryam Mobini, Reza Ali Mohammadpour, Mohammad Reza Biabani   +2 more
doaj  

Management of rheumatoid arthritis in Poland – where daily practice might not always meet evidence-based guidelines

Archives of Medical Science, 2019
Introduction International recommendations are intended to help rheumatologists in the effective management of rheumatoid arthritis (RA) through an evidence-based approach.
Bogdan Batko, Mariusz Korkosz, Anna Juś, Piotr Wiland   +3 more
doaj   +1 more source

REVIEW OF THE 2017 AMERICAN COLLEGE OF RHEUMATOLOGY/AMERICAN ASSOCIATION OF HIP AND KNEE SURGEONS GUIDELINES FOR THE PERIOPERATIVE MANAGEMENT AND ANTIRHEUMATIC THERAPY OF PATIENTS WITH RHEUMATIC DISEASES BEFORE TOTAL KNEE AND HIP ARTHROPLASTY

Научно-практическая ревматология, 2018
The article presents the guidelines developed by the American College of Rheumatology and the American Association of Hip and Knee Surgeons for the perioperative management of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic ...
V. N. Amirdzhanova, A. E. Karateev, E. Yu. Pogozheva   +2 more
doaj   +1 more source

Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study

Arthritis Research & Therapy, 2022
Background To analyse the subsequent clinical course of patients with rheumatoid arthritis (RA) who either continued or discontinued biologic agents after hospitalization for infections.
Yusuke Kashiwado, Chikako Kiyohara, Yasutaka Kimoto, Shuji Nagano, Takuya Sawabe, Kensuke Oryoji, Shinichi Mizuki, Hiroaki Nishizaka, Seiji Yoshizawa, Shigeru Yoshizawa, Tomomi Tsuru, Yasushi Inoue, Naoyasu Ueda, Shun-ichiro Ota, Yasuo Suenaga, Tomoya Miyamura, Yoshifumi Tada, Hiroaki Niiro, Koichi Akashi, Takahiko Horiuchi   +19 more
doaj   +1 more source

Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis [PDF]

The Korean Journal of Internal Medicine
Background/Aims The aim of this study was to compare the short- and long-term retention rates of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in Korean patients with seropositive rheumatoid arthritis.
Bong-Woo Lee, Jennifer Jooha Lee, Wan-Uk Kim   +2 more
doaj   +1 more source

Biological Therapies in Inflammatory Myopathies

Rambam Maimonides Medical Journal, 2023
Idiopathic inflammatory myopathies (IIM) are a rare group of disorders that feature progressive immune-mediated skeletal muscle destruction along with skin, lung, and joint involvement.
Abd El Haleem Natour, Shaye Kivity
doaj   +1 more source